Education
About Us
Working with TipRanks
Follow Us
PMV Pharmaceuticals (PMVP)
NASDAQ:PMVP
PMVP Stock Chart & Stats
$1.58
-$0.01(-0.65%)
At close: 4:00 PM EST
$1.58
-$0.01(-0.65%)
Day’s Range― - ―
52-Week Range$0.81 - $1.84
Previous CloseN/A
Volume81.53K
Average Volume (3M)2.02M
Market Cap
$71.01M
Enterprise Value-$86.12M
Total Cash (Recent Filing)$129.25M
Total Debt (Recent Filing)$931.00K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 04, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding52,990,864
10 Day Avg. Volume703,051
30 Day Avg. Volume2,020,557
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market Cap-1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.69K
Enterprise Value/Ebitda0.97
Forecast
1Y Price Target
$5.00Price Target Upside216.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressRezatapopt is progressing in the PYNNACLE Ph2 trial with strong response rates and durability.
Financial StabilityPMV Pharmaceuticals, Inc. ended with $129.3 million in cash, which should fund operations to the end of the first quarter of 2027.
Regulatory ProspectsPMV plans to submit a NDA to the FDA based on the interim data from the PYNNACLE trial for rezatapopt in ovarian cancer.
Bears Say
Commercial RisksPotential dilution risk and lower-than-projected commercial success could impact PMV Pharmaceuticals, Inc.
Development DelaysRisks include delays in moving candidates into advanced trials and setbacks in later-stage studies.
Regulatory RisksPotential risks also involve failure to obtain approval for drugs and setbacks with earlier-stage candidates.
PMV Pharmaceuticals News
PMVP FAQ
What was PMV Pharmaceuticals’s price range in the past 12 months?
PMV Pharmaceuticals lowest stock price was $0.81 and its highest was $1.84 in the past 12 months.
What is PMV Pharmaceuticals’s market cap?
PMV Pharmaceuticals’s market cap is $71.01M.
When is PMV Pharmaceuticals’s upcoming earnings report date?
PMV Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 108 days.
How were PMV Pharmaceuticals’s earnings last quarter?
PMV Pharmaceuticals released its earnings results on Nov 12, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.402 by $0.002.
Is PMV Pharmaceuticals overvalued?
According to Wall Street analysts PMV Pharmaceuticals’s price is currently Undervalued.
Does PMV Pharmaceuticals pay dividends?
PMV Pharmaceuticals does not currently pay dividends.
What is PMV Pharmaceuticals’s EPS estimate?
PMV Pharmaceuticals’s EPS estimate is -0.41.
How many shares outstanding does PMV Pharmaceuticals have?
PMV Pharmaceuticals has 52,990,864 shares outstanding.
What happened to PMV Pharmaceuticals’s price movement after its last earnings report?
PMV Pharmaceuticals reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.402. Following the earnings report the stock price went up 6.767%.
Which hedge fund is a major shareholder of PMV Pharmaceuticals?
Currently, no hedge funds are holding shares in PMVP
PMV Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (216.46% Upside)
$5.00 (216.46% Upside)
Hedge Fund Trend
Increased
By 8.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $900.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.50%
12-Months-Change
Fundamentals
Return on Equity
-51.87%
Trailing 12-Months
Asset Growth
-35.65%
Trailing 12-Months
Company Description
PMV Pharmaceuticals
PMV Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which are the most common mutations found in human cancers. The company operates within the healthcare and biotechnology sectors, aiming to provide transformative treatments that specifically target cancer's genetic drivers.
PMVP Stock 12 Month Forecast
Average Price Target
$5.00
▲(216.46% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Prelude Therapeutics
―
Gain Therapeutics
―
Immix Biopharma
―
Ownership Overview
12.76% Insiders
8.15% Mutual Funds
52.83% Other Institutional Investors
22.47% Public Companies and
Individual Investors